Accelerating the Genetic Revolution

Neurological Disorders
Muscular Dystrophies
Ocular Diseases
Oncology

A new class of synthetic medicines to address the root cause of genetic diseases

We are at a fundamental inflection point in the history of the pharmaceutical industry where, as a result of the Human Genome Project, we now have the ability to leverage nature’s own information encoding system (the genetic code) to “digitally” encode our drugs so as to target a precise gene that is malfunctioning and neutralize the disease process at its root cause.

As every human disease has genetic drivers, our vision is to dramatically reduce the suffering and death attributable to innumerable diseases across the globe with our first-in-class technology platform.

The therapies we are creating are analogous to heat-seeking missiles in that they are highly specific to only the target gene and promise easy to take and well tolerated medicines.

Technology

The advantages of the NeuBase PATrOL™ platform enable the company to cohesively develop therapies for a wide range of diseases including single-gene disorders, cancers and common diseases

NeuBase is first addressing Huntington’s disease and myotonic dystrophy

Read More

The NeuBase technology has several advantages over other precision genetic medicines

Sd

Scalable & Modular Development

Pre-organized rigid synthetic scaffold increases precision of engagement with target and toolkit of engineered nucleobases allow drugs to be quickly snapped together for many targets

Ts

Targeting Structures

Higher specificity for mutant over wild type genes, allowing for fewer off-target effects and more effective deactivation of disease-causing genes at the DNA and RNA levels

BrOD

Broad Organ Distribution

Modular delivery technologies enable targeting a variety of organ systems

Ni

No Immune Response

Therapies do not cause an immune response when systemically administered, enabling us to develop solutions for pre-symptomatic individuals who are gene mutation positive

NeuBase to Present at the Jefferies London Healthcare Conference

PITTSBURGH, Nov. 03, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present in person a corporate overview at the Jefferies London Healthcare Conference being held November 16 - 18.

Read More

NeuBase to Participate at the Chardan 5th Annual Genetic Medicines Conference

PITTSBURGH, Sept. 28, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will participate in a fireside chat at the virtual Chardan 5th Annual Genetic Medicines Conference being held October 4 - 5.

Read More

NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

PITTSBURGH, Sept. 15, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held September 20 – 23.

Read More

NeuBase Therapeutics Appoints Anthony Rossomando, Ph.D. as Chief Technology Officer

PITTSBURGH, Sept. 14, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today the appointment of Anthony Rossomando, Ph.D., as Chief Technology Officer. Dr. Rossomando has more than 25 years of experience as a biopharmaceutical drug developer who has successfully led teams from start-up to global biotechnology companies that have established the upstream and downstream process development of biologics and peptide molecules, including RNAi/siRNA, to advance multiple programs into clinical trials and commercialization in several therapeutic areas of neuroscience, rare diseases, and oncology.

Read More

close

Covid-19 Update

Read our statement related to operations during COVID-19